The use of neuromodulation as a treatment for major depressive disorder (MDD) has
recently attracted renewed interest due to development of other non-pharmacological …

About 30% of patients suffering from a major depressive disorder do not respond sufficiently
to established pharmacological, psychotherapeutic, or somatic treatments. Advances in …

Depression is the most prevalent debilitating mental illness; it is characterized as a disorder
of mood, cognitive function, and neurovegetative function. About one in ten individuals …

Major depression (MD) is characterized by the presence of depressed mood and/or
anhedonia, as well as a number of somatic, vegetative, and psychological symptoms. 1 It is …

Given that a considerable portion of depressed patients does not respond to or remit during
pharmacotherapy, there is increasing interest in non-pharmacological strategies to treat …

For many decades, psychiatric treatment has been primarily guided by two major paradigms
of psychopathology: a neurochemical paradigm leading to the development of medications …

Current first-line treatments for major depressive disorder (MDD) include pharmacotherapy
and cognitive-behavioral therapy. However, one-third of depressed patients do not achieve …

Despite best practices for the management of major depression with medications and
psychotherapy, many patients do not fully recover and need other treatment options …

Background Nearly half of the patients with depression experience suboptimal benefits from
antidepressants. Neuromodulation therapies, a kind of technology that can regulate …

Background Patients with treatment-resistant depression (TRD) who showed partial
response to pharmacological and psychotherapeutic interventions need a trial of …